- BioHarvest Sciences (BHSC) has appointed Nathaniel Averill as Vice-President of Manufacturing, Quality Assurance, and Supply Chain
- Nathaniel will bring over 25 years of experience in biotechnology pharmaceutical manufacturing to his new role
- At BioHarvest, he will assist in the set-up and development of facilities for manufacturing and showcasing company products and solutions
- Nathaniel’s appointment is well-timed, as the company is experiencing growing demand for its products across various channels
- BioHarvest Sciences is up 3.7 per cent and is currently trading for C$0.14 per share
BioHarvest Sciences (BHSC) has appointed Nathaniel Averill as Vice-President of Manufacturing, Quality Assurance, and Supply Chain.
Nathaniel will bring over 25 years of experience in biotechnology pharmaceutical manufacturing to his new role. He has been involved in the design, start-up, and management of biotech facilities for companies including Abbott Bioresearch Centre, MedImmune, and Bristol-Myers Squib.
During his career, Nathaniel played a key role in developing and producing numerous blockbuster drugs, including HUMIRA and ORENCIA. In 2012, he co-founded Healthy Pharms to produce medical marijuana, which involved the creation of a large cannabis growth facility, extraction operation, and dispensary.
At BioHarvest, Nathaniel will assist in the set-up and development of at least two company facilities. The first will be a new manufacturing facility, which will produce 20 tons of the company’s VINIA product per annum.
The second facility in Boston will provide a space for BioHarvest to showcase its unique Biofarming capabilities to the North American market. After the appropriate local state licenses are obtained, Nathaniel will convert this showcase facility into a fully operational cannabinoid producing facility in 2022.
BioHarvest’s CEO, Ilan Sobel, was privileged to welcome Nathaniel to the team.
“His wealth of experience in the most demanding industries in terms of capacity and quality will help us execute on our growth strategy and achieve our core values of customer satisfaction and quality,” he said.
“His multi-disciplinary expertise in manufacturing, Quality Assurance, and supply chain will enhance our ability to leverage our Biofarming technology to most economically produce the highest quality, most consistent nutraceuticals and cannabinoids,” he added.
Ilan went on to say that the timing of Nathaniel’s arrival could not be better, as the company is seeing growing demand for its products from both businesses and consumers.
BioHarvest Sciences is up 3.7 per cent and is trading for C$0.14 per share, as of 2:58pm EST.